{
    "root": "350160e1-34ab-f7e3-e063-6394a90a4508",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CELECOXIB",
    "value": "20250513",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "CELECOXIB",
            "code": "JCX84Q7J1L"
        }
    ],
    "indications": "Celecoxib is indicated",
    "contraindications": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. ( 2.1 ) OA: 200 mg once daily or 100 mg twice daily. ( 2.2 , 14.1 ) RA: 100 mg to 200 mg twice daily. ( 2.3 , 14.2 ) JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 kg. ( 2.4 , 14.3 ) AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit. ( 2.5 , 14.4 ) AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed. ( 2.6 , 14.5 ) Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.7 , 8.6 , 12.3 ) Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers. ( 2.7 , 8.8 , 12.3 )",
    "warningsAndPrecautions": "Celecoxib 50 mg capsules are white opaque / white opaque, size ‘4’ hard gelatin capsule printed with ‘M’ on cap and ‘11’ on the body filled with white to off white granular powder, supplied as:\n                  \n                     \n                        NDC Number\n                                     \n \n  \n                        Size\n                     \n                  \n                  42571-142-30                Bottles of 30\n                  42571-142-60                Bottles of 60\n                  42571-142-05                Bottles of 500\n                  42571-142-33                Carton of 7x10 Unit-dose Capsules  \n                  \n                  Celecoxib 100 mg capsules are white opaque / white opaque, size ‘3’ hard gelatin capsule printed with ‘M’ on cap and ‘12’ on the body filled with white to off white granular powder, supplied as:\n                  \n                     \n                        NDC Number\n                                     \n \n  \n                        Size\n                     \n                  \n                  42571-143-30                Bottles of 30\n                  42571-143-60                Bottles of 60\n                  42571-143-01                Bottles of 100        \n                  42571-143-05                Bottles of 500\n                  42571-143-33                Carton of 7x10 Unit-dose Capsules\n                  \n                  Celecoxib 200 mg capsules are white opaque / white opaque, size ‘1’ hard gelatin capsule printed with ‘M’ on cap and ‘13’ on the body filled with white to off white granular powder, supplied as:\n                  \n                     \n                        NDC Number\n                                     \n \n  \n                        Size\n                     \n                  \n                  42571-144-30                Bottles of 30\n                  42571-144-60                Bottles of 60\n                  42571-144-01                Bottles of 100\n                  42571-144-05                Bottles of 500\n                  42571-144-29                Carton of 6x10 Unit-dose Capsules\n                  \n                  Celecoxib 400 mg capsules are white opaque / white opaque, size ‘00’ hard gelatin capsule printed with ‘M’ on cap and ‘14’ on the body filled with white to off white granular powder, supplied as:\n                  \n                     \n                        NDC Number\n                                     \n \n  \n                        Size\n                     \n                  \n                  42571-145-60                Bottles of 60\n                  42571-145-05                Bottles of 500\n                  \n                  \n                     \n                        Storage\n                     \n                  \n                  Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]",
    "adverseReactions": "Celecoxib is contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product\n  \n   [see \n   \n    Warnings and Precautions (5.7, \n   \n    5.9)].\n  \n   \n                     \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients\n  \n   [see\n   \n    Warnings and Precautions (5.7,\n   \n    5.8)].\n  \n   \n                     \n                     In the setting of CABG surgery\n  \n   [see\n   \n    Warnings and Precautions (5.1)].\n  \n   \n                     \n                     In patients who have demonstrated allergic-type reactions to sulfonamides\n  \n   [see\n   \n    Warnings and Precautions (5.7)]."
}